Today's News | Note: News feeds may no longer be available for the articles on this page.

Boehringer's HIV drug has edge over bms's Reyataz 3:23 AM 7/20/2009
Reuters - USA
Patients on Boehringer Ingelheim's HIV drug Viramune run a lower risk of cardiovascular disease than Bristol Myers' blockbuster Reyataz. ...

Eli Lilly faces major challenges 6:47 AM 7/19/2009
Indianapolis Star - United States
Eli Lilly has less cash than many of its peers following the acquisition of ImClone Systems Inc. One option is to buy a biotech company or license its research. ...

Biopure files Chapter 11, plans sale 4:46 AM 7/18/2009
Boston Globe - United States
Biopure Corp which once worked on developing the human blood substitute Hemopure filed for Chapter 11 bankruptcy protection and will sell most of its remaining assets to OPK Biotech LLC. ...

Shionogi's Flu Drug as Effective as Tamiflu in Tests 2:56 AM 7/18/2009
Bloomberg - USA
Shionogi & Co said its experimental influenza drug peramivir was as effective as Roche Holding’s Tamiflu in treating flu patients in the last stage of studies required for regulatory approval. ...

Positive results push BioCryst flu drug closer to federal approval 1:05 PM 7/17/2009
Bizjournals.com - Charlotte,NC,USA
BioCryst Pharmaceuticals announced positive clinical study results for its flu drug peramivir. A single intravenous dose of peramivir performed as well as orally ingested Tamiflu in patients with uncomplicated seasonal flu. ...

Alnylam, Novartis extend deal to develop gene silencer drugs 7:43 AM 7/17/2009
Boston Globe - United States
Alnylam Pharmaceuticals Inc extended a long-standing contract with Novartis focusing on developing drugs using RNAi gene silencing technology. ...

US reviewing possible heart risks with asthma drug 4:53 PM 7/16/2009
Reuters - USA
The US FDA is reviewing if Roche and Novartis AG's asthma drug Xolair might be linked to increased risk of heart attack, abnormal heart rhythm, heart failure, and stroke. ...

Novartis Raises Forecast as Drugs for Bones, Heart Buoy Sales 5:27 AM 7/16/2009
Bloomberg - USA
Novartis AG raised its drug sales estimate citing seven new treatments including Exforge to lower blood pressure and Reclast for osteoporosis. ...

FDA panel recommends against Centocor's trabectedin 3:29 PM 7/15/2009
Bizjournals.com - Charlotte,NC,USA
The US FDA’s Oncologic Drugs Advisory Committee voted not to recommend approval of Centocor Ortho Biotech's trabectedin as part of a combination therapy with the cancer drug Doxil for patients with relapsed ovarian cancer. ...

Targacept's depression drug meets mid-stage trial goals 7:31 AM 7/15/2009
Reuters - USA
Targacept Inc's experimental depression drug TC-5214 tested with citalopram as an augmentation treatment for major depressive disorder met all the goals of a mid-stage trial. One serious adverse event - a seizure experienced by a patient. ...

Cadence says pain drug gets priority review status 6:14 AM 7/15/2009
Reuters - USA
The US FDA issued an action date of Nov 13 2009 for the new drug application (NDA) for Acetavance for the treatment of acute pain and fever in adults and children. ...

Promising Alzheimer's drug boosts toxic protein 4:38 AM 7/15/2009
Reuters - USA
Medivation Inc's promising experimental Alzheimer's drug Dimebon significantly raised levels of a toxic protein in the brains of mice adding new worries about drugs meant to remove beta amyloid protein from the brain to reverse Alzheimer's disease. ...

FDA requires label change for some transplant drugs 11:31 AM 7/14/2009
Reuters - USA
Label changes are required for Wyeth's Rapamune, Novartis' Neoral and Myfortic, and Roche's Cellcept and Sandimmune. Organ transplant patients on these drugs are at increased risk for infections such as BK virus-associated nephropathy. ...

Hisamitsu of Japan to Buy Noven Pharmaceuticals for $430M 6:48 AM 7/14/2009
Bloomberg - USA
Hisamitsu Pharmaceutical agreed to buy Noven Pharmaceuticals Inc for about $430 million. Miami-based Noven and Hisamitsu have agreed on terms of a tender offer which will last 20 days. ...

Maxygen Chemotherapy Drug Candidate Shown Safe, Effective 5:46 AM 7/14/2009
Wall Street Journal - USA
Biotechnology company Maxygen Inc said its drug candidate Maxy-G34 met safety and effectiveness goals in a midstage study. Maxy-G34 is designed to treat the blood disorder neutropenia in chemotherapy patients. ...

<- Day Earlier | Today's News